Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM

(2015) R T Bryan et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer

(2015) V. De Rosa et al.   CLINICAL CANCER RESEARCH

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update

(2015) Morgan Rouprêt et al.   EUROPEAN UROLOGY

Urinary EGFR and EpCAM predict cancer-specific survival

(2015) Peter Sidaway   Nature Reviews Urology

Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling

(2015) Xinqun Chai et al.   Scientific Reports

Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression

(2014) Shu-Ching Hsieh et al.   AMINO ACIDS

Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells

(2014) Ming Ming et al.   PLoS One

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

(2014) S. Rebouissou et al.   Science Translational Medicine

The granulocyte macrophage–colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer

(2014) Yong-tong Zhu et al.   Stem Cell Research

Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines

(2013) F. Morgillo et al.   CLINICAL CANCER RESEARCH

Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer

(2012) X. Yang et al.   CLINICAL CANCER RESEARCH

Targeting Cancer Metabolism

(2012) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinoma—Neoadjuvant and Adjuvant Settings

(2012) Cora N. Sternberg et al.   EUROPEAN UROLOGY

Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning

(2012) Michael N. Pollak   Cancer Discovery

A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer

(2010) Vincenzo Serretta et al.   BJU INTERNATIONAL

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

(2009) Daniel P. Petrylak et al.   BJU INTERNATIONAL

The Role of Bacillus Calmette-Guérin in the Treatment of Non–Muscle-Invasive Bladder Cancer

(2009) Paolo Gontero et al.   EUROPEAN UROLOGY

Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway

(2008) N. J. MacLaine et al.   MOLECULAR CANCER RESEARCH